Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07582211 · ClinicalTrials.gov registry record · NA

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma

A NA study, sponsored by Columbia University.

Not yet
Registry status
NA
Development phase
36
Enrollment target

NCT07582211 is a NA study that has not yet begun recruiting, run by Columbia University. The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07582211, a NA study, has not yet begun recruiting, sponsored by Columbia University.

NOT YET RECRUITING
Registry status
NA
Development phase
36 participants
Enrollment target

Study Summary

The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach. The main questions it aims to answer are: 1. Can eligible patients be successfully enrolled and complete study procedures across multiple sites? 2. What safety events occur with early BPAP use in this population? 3. How do clinical outcomes (such as symptom improvement and need for intensive care) compare between early BPAP and standard care? Researchers will compare early initiation of BPAP plus standard asthma therapy to standard asthma therapy alone to determine whether early BPAP is a feasible and potentially beneficial treatment strategy. Participants will 1) receive standard asthma therapy with or without early BPAP in the ED, 2) be monitored closely during the ED visit and hospitalization, and 3) have clinical data collected from routine care, including asthma severity scores, treatments, and outcomes. The study will enroll approximately 36 participants (about 12 per site) across three sites over one year to inform a future multicenter randomized controlled trial.

Interventions

  • DEVICE Bilevel positive airway pressure ventilation

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2026-06
Est. Completion 2027-08
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT07582211

The ClinicalTrials.gov registry entry for NCT07582211 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Bilevel positive airway pressure ventilation is the first listed.

NCT07582211 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07582211 about?

NCT07582211 is a clinical study titled "Bilevel Positive Airway Pressure (BPAP) for Severe Asthma". The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach...

What is the current status of trial NCT07582211?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2026-06. Estimated completion is 2027-08.

What interventions are being tested in trial NCT07582211?

The interventions under investigation include: Bilevel positive airway pressure ventilation (DEVICE).

Who is sponsoring clinical trial NCT07582211?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.